Why Does the Scale Refuse to Move When You're Doing Everything Right?

Estradiol acts directly on insulin receptors in skeletal muscle and liver tissue, enhancing insulin sensitivity. When estrogen declines during perimenopause, insulin sensitivity drops in tandem. This is not a minor footnote in endocrinology textbooks. It is the central metabolic event of the menopausal transition and it affects virtually every organ system. According to Mauvais-Jarvis, who published a landmark 2017 paper on this connection, up to 40 percent of women over 40 develop clinically significant insulin resistance, often years before any glucose abnormality appears on standard blood work. I want you to absorb that number. Four in ten women. And the standard test, fasting glucose, does not catch it at the early reversible stage. The HOMA-IR index, calculated from fasting insulin divided by fasting glucose times a constant, catches this shift early. A score above 2.0 suggests developing resistance. Above 2.5 is clinically significant. But fasting insulin is not included in routine screening panels in most countries. Women whose blood glucose reads normal may already have fasting insulin levels five times optimal. Their metabolism is already in fat-storage mode. And they are being told to eat less. I find that maddening. Losing weight with insulin resistance that nobody has diagnosed is like trying to drive a car with the parking brake engaged while your mechanic insists the engine is fine. The evidence base for early insulin screening in at-risk women is strong. The Diabetes Prevention Program showed that lifestyle intervention reduced progression to type 2 diabetes by 58 percent in people with prediabetes. Imagine what early detection, years before prediabetes, could accomplish. But we cannot intervene on what we do not detect. And we are not detecting it.